Posts by: Alice Melão

Alice Melão

January 22, 2019January 22, 2019

Enrollment Completed for Phase 2 Trial Testing VX15/2503 in Early and Late Prodromal Huntington’s Patients

News

Vaccinex has completed its target enrollment in a Phase 2 clinical trial assessing the potential of the investigational antibody VX15/2503 (pepinemab) as a treatment for patients with early manifest and late prodromal ... Read more

October 23, 2018October 23, 2018

Gene Therapy VY-HTT01 Can Protect Brain Cells from Damage Caused by HTT Faulty Gene, Results Show

News

One-time delivery of Voyager Therapeutics’ lead candidate gene therapy, VY-HTT01, effectively reduced the levels of the faulty gene responsible for Huntington’s disease in important brain areas of non-human large primates. These positive ... Read more

October 9, 2018October 9, 2018

Northwestern University Receives $12.6 Million to Study Protein Balance Mechanisms in Health and Disease

News

The National Institute on Aging at the National Institutes of Health (NIH) has granted $12.6 million to Northwestern University to study the role of protein quality control mechanisms in human ... Read more

September 18, 2018September 18, 2018

New Test Could Help Predict Onset, Course of Huntington’s, Lab Researchers Say

News

Short huntingtin (HTT) protein fibers precede the formation of larger deposits that accumulate in the brains of those affected by Huntington’s disease, preclinical results reveal. These findings one day may help ... Read more

August 7, 2018September 21, 2018

PRIME Designation Should Help Promising Experimental Therapy Reach Huntington’s Patients Faster

News

The European Medicines Agency (EMA) has granted Priority Medicine (PRIME) designation to Roche’s investigational therapy RG6042 for the treatment of Huntington’s disease. PRIME provides a pathway for expedited assessment and ... Read more

July 25, 2018

Phase 2a Trial Investigates BP Medicine SOM3355 as Treatment for Chorea

News

SOM3355 — a medicine approved for high blood pressure and chest pain — is being tested in a Phase 2 trial as a means to treat chorea in Huntington’s disease patients, SOM Biotech announced. ... Read more

July 10, 2018July 10, 2018

Improved Genetic Testing Protocols Should be Available for Huntington’s Disease, Study Contends

News

Adequate support and follow-up should be considered when implementing and designing pre-symptomatic genetic testing for Huntington’s disease, a study has revealed. The study, “Perspectives on Genetic Testing and Return of ... Read more

June 28, 2018June 28, 2018

Experts Seeking Tools to Assess Effectiveness of Targeted Huntington’s Therapies

News

Improved measures to accurately determine the effectiveness of treatments targeting Huntington’s disease are necessary, according to clinical neurologists and Huntington’s specialists. The editorial, “Improved metrics for Huntington’s disease trials,” reflects ... Read more

June 21, 2018June 21, 2018

New Huntingtin Protein Strategy Significantly Improves Symptoms Over Time, Study Finds

Huntington's Disease News, News

A new therapeutic strategy based on a small part of the huntingtin protein — which in a mutated form is responsible for Huntington’s disease — shows potential to regulate the ... Read more

May 29, 2018May 29, 2018

Apathy Linked to Physical, Cognitive and Behavioral Disability in Huntington’s Patients, Study Finds

News

Apathy is linked to physical, cognitive, and behavioral impairments in patients with Huntington’s disease, a study shows. The study, “Relationships Among Apathy, Health-Related Quality of Life, and Function in Huntington’s ... Read more